The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
BLENREP GlaxoSmithKline Australia Pty Ltd
Product name
BLENREP
Accepted date
Jan-2025
Active ingredients
belantamab mafodotin
Proposed indication
Belantamab mafodotin is used to treat patients with multiple myeloma that has come back or did not respond to treatment. It is for patients who have already tried at least two other treatments, including a proteasome inhibitor and an immunomodulatory agent.
Application type
A (new medicine)
Publication date
Jan-2025